title: Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimens.
abstract: There are limited data about dyslipidemia in Asian patients treated with combination antiretroviral therapy. To assess the relative association of different protease-inhibitor-containing regimens with the degree of dyslipidemia, fasting lipid levels were compared during 110 weeks in 250 nucleoside-experienced but protease-inhibitor-naïve Thai patients beginning treatment with 5 protease-inhibitor-containing regimens. Regimens were (1) stavudine, didanosine, and saquinavir; (2) zidovudine, lamivudine, and saquinavir; (3) zidovudine, lamivudine, and indinavir; (4) zidovudine, lamivudine, and ritonavir-boosted indinavir; and (5) efavirenz and ritonavir-boosted indinavir. Triglyceride levels were available for all patients; total cholesterol and high-densitylipoprotein cholesterol levels were available for patients receiving indinavir. The strongest predictors of dyslipidemia after beginning protease-inhibitor-based therapy were treatment regimen and baseline dyslipidemia. Triglycerides, total cholesterol, and high-density-lipoprotein cholesterol changes from baseline to week 110 were significant in patients taking ritonavir-boosted indinavir. Efavirenz and ritonavir-boosted indinavir were associated with significant high-density-lipoprotein cholesterol increases compared with other regimens. Non-stavudine-containing non-boosted protease-inhibitor-based highly active antiretroviral treatment regimens had the least association with dyslipidemia.
authors.affiliation: The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand. s.kerr@unsw.edu.au
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Kerr
authors.forename: Chris
authors.initials: C
authors.lastname: Duncombe
authors.forename: Anchalee
authors.initials: A
authors.lastname: Avihingsanon
authors.forename: Jintanat
authors.initials: J
authors.lastname: Ananworanich
authors.forename: Mark
authors.initials: M
authors.lastname: Boyd
authors.forename: Bunruan
authors.initials: B
authors.lastname: Sopa
authors.forename: B
authors.initials: B
authors.lastname: Medtech
authors.forename: Theshinee
authors.initials: T
authors.lastname: Chuenyam
authors.forename: David A
authors.initials: DA
authors.lastname: Cooper
authors.forename: Joep M A
authors.initials: JM
authors.lastname: Lange
authors.forename: Praphan
authors.initials: P
authors.lastname: Phanuphak
authors.forename: Kiat
authors.initials: K
authors.lastname: Ruxrungtham
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D044466:Asian People; D004334:Drug Administration Schedule; D050171:Dyslipidemias / Q000139:chemically induced / Q000208:ethnology*; D005260:Female; D015658:HIV Infections / Q000097:blood* / Q000188:drug therapy* / Q000208:ethnology; D017320:HIV Protease Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008055:Lipids / Q000097:blood*; D008297:Male; D012189:Retrospective Studies; D013785:Thailand; D019562:Viral Load
chemical_list: D017320:HIV Protease Inhibitors; D008055:Lipids